Advanced Filters
noise

Semaglutide Clinical Trials

A listing of Semaglutide medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 63 clinical trials

Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 …

12 - 18 years of age All Phase 3
P Project Manager

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult …

18 - 65 years of age All Phase 4
N Nicole Maser, MSN RN

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

18 years of age All Phase 2
M Miriam Kolko, MD, Phd

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram. …

45 years of age All Phase 4
S Silvana Pannain, MD

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

18 - 75 years of age All Phase 3
K Krista Jong

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. …

18 - 80 years of age All Phase N/A
J Jorge Valdespino Valdes, MD

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus …

18 years of age All Phase 4
L Luis G D'Marco, M.D; Ph.D.

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

Obesity is considered a global pandemic and is associated with various diseases and metabolic complications, such as type 2 diabetes mellitus, high blood pressure, cholesterol disorders, cancer, cardiovascular disease, and kidney disease. Obesity can affect the kidneys in two main ways: indirectly, through mechanisms related to diabetes mellitus and/or high …

18 years of age All Phase N/A
J Julie Sorg, MSN

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the …

18 years of age All Phase N/A
J Jianping Liu

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants …

18 - 75 years of age All Phase 4

Simplify language using AI